Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2015 Publisher: Bausch & Lomb UK Limited, Bausch & Lomb House, 106 London Road, Kingston-Upon-Thames, Surrey, UK, KT2 6TN
Proxymetacaine hydrochloride, in common with other local anaesthetics, reversibly blocks the initiation and conduction of nerve impulses by decreasing the permeability of the neuronal membrane to sodium ions.
The delay to onset of effect, duration of effect and potency of Proxymetacaine hydrochloride are similar to those of amethocaine.
Proxymetacaine hydrochloride is readily absorbed into the systemic circulation where, in common with other ester-type local anaesthetics, it is hydrolysed by plasma esterases. Proxymetacaine hydrochloride is also subject to hepatic metabolism.
No adverse safety issues were identified during the development of this formulation. The ingredients are well established in clinical ophthalmology.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
